लोड हो रहा है...
"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Da...
में बचाया:
मुख्य लेखकों: | , , |
---|---|
स्वरूप: | Artigo |
भाषा: | Inglês |
प्रकाशित: |
BioMed Central
2006
|
विषय: | |
ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1538598/ https://ncbi.nlm.nih.gov/pubmed/16822312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-4-40 |
टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|